Nanoscope Therapeutics Inc., a company based in Bedford, Texas, has reported the completion of enrollment for a Phase 2 study for Stargardt disease. The study… Read More »Nanoscope Therapeutics Inc., have announced the completion of enrolment for Phase 2 Stargardt disease study with optogenetic gene therapy
Researchers at the Institute of Applied Ophthalmobiology (IOBA), University of Valladolid, Spain, has reported results on the use of hair cortisol concentrations (HCC), measuring chronic… Read More »EURETINA Hamburg 2022: Spanish researchers report that hair cortisol level may be used as a molecular biomarker in retinitis pigmentosa patients
Researchers at the Coimbra Institute for Clinical and Biomedical Research, University of Coimbra, Portugal, have reported a clear association between rare genetic variants in complement… Read More »The Coimbra Eye Study has identified phenotypic differences between carriers and non-carriers of rare variants of the CFH gene
by Dr. Gearóid Tuohy Dear EURETINA Members, A very warm welcome to the September 30, 2022 edition of EURETINA’s web-based digital magazine, “EURETINA… Read More »September 30th, 2022 “EURETINA-Brief”© Issue No. 260
Coherus BioSciences, Inc. (NASDAQ: CHRS) has announced approval of CIMERLI (ranibizumab-eqrn), a biosimilar product interchangeable with Lucentis (ranibizumab injection) for all five indications – for… Read More »Coherus BioSciences, Inc. (NASDAQ: CHRS), has announced the approval of “CIMERL” a biosimilar interchangeable to Lucentis for all five indications (AMD, RVO, DME, DR and mCNV).
Researchers at the Association for Innovation and Biomedical Research on Light and Image (AIBILI), Coimbra, and the University of Coimbra, Portugal, has reported phenotypic differences… Read More »Clinical researchers on rare variants of the CFH gene has reported significant burden of disease among AMD patients
Researchers at the Centre Psychothérapique de Nancy, France, has reported that retinal electrophysiological markers may act as indicators of therapeutic responses in depressed patients in… Read More »Retinal function and retinal markers shows responses on anti-depressant treatment of major depressive disorder (MDD)
by Dr. Gearóid Tuohy Dear EURETINA Members, A very warm welcome to the August 17th, 2022 edition of EURETINA’s web-based digital magazine, “EURETINA… Read More »August 17th, 2022 “EURETINA-Brief”© Issue No. 259
Opus Genetics Inc., a private ocular gene therapy company based in Raleigh, North Carolina, has announced new preclinical data from studies evaluating gene therapies, termed… Read More »Opus Genetics (Raleigh, North Carolina) has announced new preclinical data from studies evaluating gene therapies for OPGx-001 and OPGx-002.
Researchers in the Diabetic Retinopathy Clinical Research (DRCR) Retina Network has reported that the treatment of moderate vision loss due to diabetic macular edema found… Read More »Aflibercept monotherapy or “bevacizumab first” for diabetic macular edema assessed the evidence on visual outcomes and costs to the healthcare system.